Symbols / BCDA $1.28 +0.79%
BCDA Chart
About
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.58M |
| Enterprise Value | 8.83M | Income | -8.54M | Sales | — |
| Book/sh | 0.25 | Cash/sh | 0.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -1.86 | PEG | — |
| P/S | inf | P/B | 5.16 | P/C | — |
| EV/EBITDA | -1.03 | EV/Sales | — | Quick Ratio | 1.60 |
| Current Ratio | 1.62 | Debt/Eq | 24.29 | LT Debt/Eq | — |
| EPS (ttm) | -1.42 | EPS next Y | -0.69 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 16:00 | ROA | -86.45% |
| ROE | -3.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 10.61M |
| Shs Float | 7.20M | Short Float | 2.47% | Short Ratio | 3.34 |
| Short Interest | — | 52W High | 3.20 | 52W Low | 1.00 |
| Beta | 0.55 | Avg Volume | 80.01K | Volume | 210.81K |
| Target Price | $15.50 | Recom | None | Prev Close | $1.27 |
| Price | $1.28 | Change | 0.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.50
Mean price target
2. Current target
$1.28
Latest analyst target
3. DCF / Fair value
$-7.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.28
Low
$6.00
High
$25.00
Mean
$15.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-10-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-16 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-10-11 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-09-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-07-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-06-21 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-05-11 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-03-30 | reit | HC Wainwright & Co. | — → Buy | $9 |
| 2022-11-11 | down | Dawson James | Buy → Neutral | — |
| 2021-12-20 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2021-04-16 | down | Dawson James | Buy → Neutral | — |
| 2020-09-21 | init | Alliance Global Partners | — → Buy | $12 |
- FDA to review new heart catheter for cell and gene therapy delivery - Stock Titan ue, 17 Mar 2026 10
- BioCardia® Announces FDA Acceptance of Pre-Submission Package for Helix Transendocardial Delivery Catheter - Quiver Quantitative ue, 17 Mar 2026 10
- BCDA Stock Price, Quote & Chart | BIOCARDIA INC (NASDAQ:BCDA) - ChartMill Fri, 13 Mar 2026 07
- Altman Peter buys BioCardia (BCDA) shares worth $1,194 - Investing.com Wed, 21 Jan 2026 08
- FDA accepts BioCardia (NASDAQ: BCDA) Helix catheter pre-submission for review - Stock Titan ue, 17 Mar 2026 10
- Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off - Yahoo Finance Sat, 20 Sep 2025 07
- Insiders' US$1.06m Investments In Red Following BioCardia's US$117k Dip In Market Value - simplywall.st Sat, 20 Sep 2025 07
- BioCardia Executives Make Bold Moves with Major Stock Purchases - TipRanks ue, 23 Sep 2025 07
- Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus Wed, 21 Jan 2026 08
- BioCardia Faces Market Slump as Resale Registration Trigger Shares Drop - StocksToTrade Mon, 04 Aug 2025 07
- Heart failure cell therapy shows less adverse cardiac remodeling - Stock Titan ue, 03 Mar 2026 08
- Biocardia director Blank buys $360k in common stock - Investing.com ue, 23 Sep 2025 07
- Why BioCardia (BCDA) Stock Is Up 95% Today - TradingView hu, 29 Aug 2024 07
- BioCardia’s Stock Dilemma: Opportunity or Risk? - StocksToTrade hu, 18 Sep 2025 07
- BioCardia to Participate in Fireside Chat at A.G.P. Virtual Heal - GuruFocus Wed, 21 May 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5000 | 5650 | — | Purchase at price 1.13 per share. | ALTMAN PETER | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 1 | 900 | 1194 | — | Purchase at price 1.32 - 1.34 per share. | ALTMAN PETER | Chief Executive Officer | — | 2026-01-21 00:00:00 | D |
| 2 | 1100 | 1444 | — | Purchase at price 1.30 - 1.37 per share. | ALTMAN PETER | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
| 3 | 38078 | 52167 | — | Stock Award(Grant) at price 1.37 per share. | GILLIS EDWARD M | Officer | — | 2025-12-08 00:00:00 | D |
| 4 | 58276 | 79838 | — | Stock Award(Grant) at price 1.37 per share. | MCCLUNG DAVID | Chief Financial Officer | — | 2025-12-08 00:00:00 | D |
| 5 | 106588 | 146026 | — | Stock Award(Grant) at price 1.37 per share. | ALTMAN PETER | Chief Executive Officer | — | 2025-12-08 00:00:00 | D |
| 6 | 48000 | 60000 | — | Purchase at price 1.25 per share. | ALTMAN PETER | Chief Executive Officer | — | 2025-09-19 00:00:00 | D |
| 7 | 398400 | 498000 | — | Purchase at price 1.25 per share. | STERTZER SIMON H | Director | — | 2025-09-19 00:00:00 | I |
| 8 | 288000 | 360000 | — | Purchase at price 1.25 per share. | BLANK ANDREW SCOTT | Director | — | 2025-09-19 00:00:00 | I |
| 9 | 700 | 1281 | — | Purchase at price 1.83 per share. | ALTMAN PETER | Chief Executive Officer | — | 2025-08-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -7.93M | -11.56M | -11.82M | -12.57M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.95M | -11.57M | -11.91M | -12.62M |
| ReconciledDepreciation | 67.00K | 84.00K | 82.00K | 60.00K |
| ReconciledCostOfRevenue | 0.00 | |||
| EBITDA | -7.93M | -11.56M | -11.82M | -12.57M |
| EBIT | -8.00M | -11.64M | -11.90M | -12.63M |
| NetInterestIncome | 9.00K | |||
| InterestExpense | 0.00 | |||
| InterestIncome | 9.00K | |||
| NormalizedIncome | -7.95M | -11.57M | -11.91M | -12.62M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.95M | -11.57M | -11.91M | -12.62M |
| TotalExpenses | 8.06M | 12.12M | 13.25M | 13.64M |
| TotalOperatingIncomeAsReported | -8.00M | -11.64M | -11.90M | -12.63M |
| DilutedAverageShares | 2.74M | 1.41M | 1.18M | 1.13M |
| BasicAverageShares | 2.74M | 1.41M | 1.18M | 1.13M |
| DilutedEPS | -2.90 | -8.19 | -10.05 | -11.25 |
| BasicEPS | -2.90 | -8.19 | -10.05 | -11.25 |
| DilutedNIAvailtoComStockholders | -7.95M | -11.57M | -11.91M | -12.62M |
| NetIncomeCommonStockholders | -7.95M | -11.57M | -11.91M | -12.62M |
| NetIncome | -7.95M | -11.57M | -11.91M | -12.62M |
| NetIncomeIncludingNoncontrollingInterests | -7.95M | -11.57M | -11.91M | -12.62M |
| NetIncomeContinuousOperations | -7.95M | -11.57M | -11.91M | -12.62M |
| PretaxIncome | -7.95M | -11.57M | -11.91M | -12.62M |
| OtherIncomeExpense | 55.00K | 73.00K | -6.00K | 7.00K |
| OtherNonOperatingIncomeExpenses | 55.00K | 73.00K | -6.00K | 7.00K |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 9.00K | |||
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 9.00K | |||
| OperatingIncome | -8.00M | -11.64M | -11.90M | -12.63M |
| OperatingExpense | 8.06M | 12.12M | 13.25M | 13.64M |
| ResearchAndDevelopment | 4.39M | 7.73M | 8.83M | 8.56M |
| SellingGeneralAndAdministration | 3.67M | 4.39M | 4.42M | 5.09M |
| GrossProfit | 1.01M | |||
| CostOfRevenue | 0.00 | |||
| TotalRevenue | 58.00K | 477.00K | 1.35M | 1.01M |
| OperatingRevenue | 58.00K | 477.00K | 1.35M | 1.01M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 4.60M | 1.58M | 1.34M | 1.12M |
| ShareIssued | 4.60M | 1.58M | 1.34M | 1.12M |
| TotalDebt | 951.00K | 1.31M | 1.63M | 1.87M |
| TangibleBookValue | 837.00K | -1.60M | 4.89M | 10.38M |
| InvestedCapital | 837.00K | -1.60M | 4.89M | 10.38M |
| WorkingCapital | 301.00K | -2.15M | 4.28M | 9.77M |
| NetTangibleAssets | 837.00K | -1.60M | 4.89M | 10.38M |
| CapitalLeaseObligations | 951.00K | 1.31M | 1.63M | 1.87M |
| CommonStockEquity | 837.00K | -1.60M | 4.89M | 10.38M |
| TotalCapitalization | 837.00K | -1.60M | 4.89M | 10.38M |
| TotalEquityGrossMinorityInterest | 837.00K | -1.60M | 4.89M | 10.38M |
| StockholdersEquity | 837.00K | -1.60M | 4.89M | 10.38M |
| RetainedEarnings | -160.12M | -152.18M | -140.60M | -128.70M |
| AdditionalPaidInCapital | 160.95M | 150.57M | 145.48M | 139.06M |
| CapitalStock | 5.00K | 2.00K | 20.00K | 17.00K |
| CommonStock | 5.00K | 2.00K | 20.00K | 17.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.89M | 4.59M | 4.90M | 5.34M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 566.00K | 982.00K | 1.32M | 1.63M |
| LongTermDebtAndCapitalLeaseObligation | 566.00K | 982.00K | 1.32M | 1.63M |
| LongTermCapitalLeaseObligation | 566.00K | 982.00K | 1.32M | 1.63M |
| CurrentLiabilities | 2.32M | 3.61M | 3.58M | 3.71M |
| CurrentDeferredLiabilities | 532.00K | 561.00K | 965.00K | 1.53M |
| CurrentDeferredRevenue | 532.00K | 561.00K | 965.00K | 1.53M |
| CurrentDebtAndCapitalLeaseObligation | 385.00K | 333.00K | 315.00K | 237.00K |
| CurrentCapitalLeaseObligation | 385.00K | 333.00K | 315.00K | 237.00K |
| PayablesAndAccruedExpenses | 1.40M | 2.71M | 2.31M | 1.94M |
| CurrentAccruedExpenses | 1.02M | 1.75M | 1.60M | 1.44M |
| Payables | 385.00K | 961.00K | 701.00K | 507.00K |
| DuetoRelatedPartiesCurrent | 0.00 | 71.00K | 18.00K | 0.00 |
| AccountsPayable | 385.00K | 890.00K | 683.00K | 507.00K |
| TotalAssets | 3.72M | 2.99M | 9.79M | 15.72M |
| TotalNonCurrentAssets | 1.10M | 1.53M | 1.93M | 2.24M |
| OtherNonCurrentAssets | 171.00K | 171.00K | 171.00K | 172.00K |
| NetPPE | 931.00K | 1.36M | 1.76M | 2.06M |
| AccumulatedDepreciation | -761.00K | -694.00K | -619.00K | -537.00K |
| GrossPPE | 1.69M | 2.05M | 2.38M | 2.60M |
| Leases | 26.00K | 26.00K | 26.00K | 26.00K |
| ConstructionInProgress | 0.00 | 74.00K | ||
| OtherProperties | 1.47M | 1.84M | 2.16M | 2.34M |
| MachineryFurnitureEquipment | 192.00K | 188.00K | 188.00K | 159.00K |
| BuildingsAndImprovements | 1.59M | 1.88M | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.62M | 1.46M | 7.86M | 13.48M |
| OtherCurrentAssets | 251.00K | 295.00K | 300.00K | 462.00K |
| PrepaidAssets | 462.00K | |||
| Receivables | 0.00 | 63.00K | 201.00K | 147.00K |
| DuefromRelatedPartiesCurrent | 0.00 | |||
| AccountsReceivable | 0.00 | 63.00K | 201.00K | 147.00K |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | -34.00K | -11.00K | -22.00K |
| GrossAccountsReceivable | 0.00 | 97.00K | 212.00K | 169.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.37M | 1.10M | 7.36M | 12.87M |
| CashAndCashEquivalents | 2.37M | 1.10M | 7.36M | 12.87M |
| CashEquivalents | 2.00K | 2.00K | 6.89M | 12.92M |
| CashFinancial | 2.37M | 1.10M | 470.00K | -45.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.03M | -9.99M | -10.63M | -10.48M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 10.55M | 4.39M | 5.54M | 2.00M |
| CapitalExpenditure | -6.00K | -12.00K | -70.00K | -116.00K |
| EndCashPosition | 2.37M | 1.10M | 7.36M | 12.87M |
| BeginningCashPosition | 1.10M | 7.36M | 12.87M | 21.41M |
| ChangesInCash | 1.27M | -6.26M | -5.51M | -8.54M |
| FinancingCashFlow | 9.30M | 3.73M | 5.12M | 1.95M |
| CashFlowFromContinuingFinancingActivities | 9.30M | 3.73M | 5.12M | 1.95M |
| NetOtherFinancingCharges | -1.25M | -662.00K | -418.00K | -59.00K |
| ProceedsFromStockOptionExercised | 0.00 | 5.00K | ||
| NetCommonStockIssuance | 10.55M | 4.39M | 5.54M | 2.00M |
| CommonStockIssuance | 10.55M | 4.39M | 5.54M | 2.00M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -6.00K | -12.00K | -70.00K | -116.00K |
| CashFlowFromContinuingInvestingActivities | -6.00K | -12.00K | -70.00K | -116.00K |
| NetPPEPurchaseAndSale | -6.00K | -12.00K | -70.00K | -116.00K |
| PurchaseOfPPE | -6.00K | -12.00K | -70.00K | -116.00K |
| OperatingCashFlow | -8.03M | -9.97M | -10.56M | -10.37M |
| CashFlowFromContinuingOperatingActivities | -8.03M | -9.97M | -10.56M | -10.37M |
| ChangeInWorkingCapital | -1.22M | 129.00K | -214.00K | -63.00K |
| ChangeInOtherWorkingCapital | -341.00K | -506.00K | 164.00K | |
| ChangeInOtherCurrentLiabilities | -364.00K | -316.00K | -237.00K | -642.00K |
| ChangeInOtherCurrentAssets | 580.00K | |||
| ChangeInPayablesAndAccruedExpense | -994.00K | 666.00K | 420.00K | -109.00K |
| ChangeInAccruedExpense | -678.00K | 482.00K | 416.00K | 130.00K |
| ChangeInPayable | -316.00K | 184.00K | 4.00K | -239.00K |
| ChangeInAccountPayable | -316.00K | 184.00K | 4.00K | -239.00K |
| ChangeInPrepaidAssets | 44.00K | 5.00K | 163.00K | -179.00K |
| ChangeInInventory | 0.00 | |||
| ChangeInReceivables | 97.00K | 115.00K | -54.00K | 703.00K |
| ChangesInAccountReceivables | 97.00K | 115.00K | -54.00K | 85.00K |
| StockBasedCompensation | 741.00K | 1.03M | 1.18M | 1.66M |
| ProvisionandWriteOffofAssets | -34.00K | 23.00K | ||
| AssetImpairmentCharge | 295.00K | 580.00K | ||
| DepreciationAmortizationDepletion | 67.00K | 84.00K | 82.00K | 60.00K |
| DepreciationAndAmortization | 67.00K | 84.00K | 82.00K | 60.00K |
| Depreciation | 67.00K | 84.00K | 82.00K | 60.00K |
| OperatingGainsLosses | 363.00K | 331.00K | 295.00K | 19.00K |
| GainLossOnSaleOfPPE | 363.00K | 331.00K | 295.00K | 19.00K |
| NetIncomeFromContinuingOperations | -7.95M | -11.57M | -11.91M | -12.62M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCDA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|